News

We are excited to announce that preclinical data on COR-1389, the first-in-class and best-in-class CRF2 receptor agonist, will be presented at EASD 2026 in Milan! COR-1389 is designed to deliver weight loss while increasing lean muscle mass, offering a fundamentally different and efficient approach to obesity treatment.  COR-1389 is finishing  its Phase 1 in

COR-1167 is entering Phase 2 clinical trial for the treatment of Worsening Heart Failure after obtaining promising Phase 1 data, while the Phase 1 of COR-1389 is ongoing for the treatment of Obesity and Right Heart Failure. Philip Janiak, Corteria’s CEO said:“The robust preclinical data, together with the emerging clinical data, strengthen our confidence

Two communications have been made at the AHA 2024 in Chicago on COR-1167 and COR-1389:

New preclinical data of COR-1389 in a model of right heart failure (RHF) were presented at the ESC 2024 in London.  Chronic CRF2 agonism with COR-1389 improved dysregulated cardiac and pulmonary function and structure in a RHF rat model, suggesting its potential for the treatment of PH and RHF.

At ESC HF 2024 in Lisbon, during an oral presentation, new data data of our CRF2 peptide agonist COR-1167 were released. On top of furosemide, COR-1167 reduced elevated cardiac filling and venous pressures, increased diuresis, decreased body weight and improved renal function in a worsening heart failure sheep model, even under conditions of fluid

Corteria team is very proud to announce the initiation of COR-1167 first-in-human study. COR-1167 is a first-in-class corticotropin-releasing hormone receptor 2 (CRF2) agonist. A significant milestone toward a treatment for worsening heart failure. Full PR is available here :https://corteriapharma.com/wp-content/uploads/2024/03/Corteria-PR-FIM-COR-1167-EN.pdf

Paris (France), 05 January 2024 – Corteria Pharmaceuticals (“Corteria”), a biopharmaceutical company specialized in the development of transformative therapies for heart failure and obesity, today announced it has appointed Mark Pruzanski, MD, as Chairman of its Board of Directors. He replaces Thierry Laugel, Managing Partner at Kurma Partners, who remains a member of the

At AHA 2023, the last results of COR-1167 in a sheep model of Worsening Heart Failure, developed by M. Rademaker (Univ. Otago, NZ) were presented: Furosemide at a dose that promotes natriuresis/diuresis had no effect on cardiac pressures or function. The combination of COR-1167 plus furosemide reduced Left Atrial Pressure, Left Ventricular End Diastolic

Paris (France), 07 September 2023 – Corteria Pharmaceuticals (“Corteria”), a biopharmaceutical company specialized in the development of transformative therapies for unaddressed heart failure subpopulations, today announced an oversubscribed €65M ($71M1) Series A co-led by US investment firm OrbiMed and EU-based leading investment firm Jeito Capital, with the participation of all existing seed investors (Kurma

At ESC 2023, the acute effects of the new long-acting CRF2 selective agonist COR-1167 in a rat model of heart failure with reduced ejection fraction were presented for the first time ! COR-1167 rapidly improved cardiac function through its mild positive inotropic and marked lusitropic effects after a single subcutaneous injection demonstrating that CRF2 receptor

Instead of targeting broad heterogenous chronic heart failure populations, at Corteria, we are addressing well defined heart failure subpopulations that are most likely to benefit from our treatments: learn more about Corteria Pharmaceuticals strategy and portfolio at https://lnkd.in/gncbAv4r